A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Diabetes Mellitus, Type 2
In brief
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
Key facts
- Study ID
- NCT07590193
- Run by
- Amgen
- People needed
- 162
- Starts
- 2026-06-11
- Expected to finish
- 2027-10-02
- Last updated by the study team
- 2026-08-03
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orange County Research Center — Lake Forest, California, United States (enrolling)
- Translational Clinical Research LLC — Aventura, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.